The DBT-BIRAC supported India’s first mRNA-based vaccine has received nod from the Drugs Controller General of India (DCGI) for phase II/III trial.

Gennova Biopharmaceuticals Ltd., the Pune-based biotechnology company, submitted the interim clinical data of the phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India's National Regulatory Authority (NRA).

Vaccine Subject Expert Committee (SEC) reviewed the interim phase I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.

Gennova submitted the proposed phase II and phase III study entitled "A prospective, multicentre, randomized, active-controlled, observer-blind, phase II study seamlessly followed by a phase III study to evaluate the safety, tolerability, and immunogenicity of the candidate HGCO19 (Covid-19 vaccine) in healthy subjects" which was approved by the office of the DCG(I), CDSCO.

The study will be conducted in India at approximately 10-15 sites in phase II and 22-27 sites in phase III. Gennova plans to use the DBT-ICMR clinical trial network sites for this study.

Gennova's mRNA-based Covid-19 vaccine development programme was partly funded by the Department of Biotechnology (DBT), Government of India under Ind CEPI, way back in Jun 2020. Later on, the DBT further supported the programme under the Mission Covid Suraksha- The Indian Covid-19 vaccine Development Mission, implemented by BIRAC.

Dr Renu Swarup, Secretary, DBT and Chairperson, BIRAC said that “It is a matter of great pride that Nation’s first mRNA-based vaccine is found to be safe and the Drugs Controller General of India has approved phase II/III trial. We are confident that this will be an important vaccine for both India and the world. This is an important milestone in our Indigenous Vaccine Development Mission and positions India on the Global Map for Novel Vaccine Development."